Bill Janeway Discusses Twitter Inc (TWTR)’s Global Prospects

Bill Janeway, managing director at Warburg Pincus, in an interview on Bloomberg discussed the growth prospects of Twitter Inc (NYSE:TWTR), a social media company that is trying hard to catch up or even dethrone Facebook Inc (NASDAQ:FB) as the global go-place for advertisers.


Although Twitter Inc (NYSE:TWTR) trails Facebook Inc (NASDAQ:FB) by a huge margin in terms of monthly active users, Janeway said what currently matters for Twitter is attaining positive cash flow. Once that happens, he said many positive things will start happening, and the company will strengthen overtime in terms of user numbers and balance sheet.

While providing insight into what Twitter Inc (NYSE:TWTR)’s growth prospect, Janeway recalled the experimentation spanning nearly 50 years when people worked hard to build computers that not only work but that are also distributable and mobile. He went on to say that Twitter is in the early stages of experimenting, and the company is a prime example of experimentation in the social media. “Now is the time for experimentation. Twitter is a prime example of experimenting on the frontier,” Janeway observed.

Janeway believes that Twitter Inc (NYSE:TWTR) has a huge growth potential whereby he cites opportunities in mobile advertising where location services are integrated with social media. He said mobile advertising of that nature is going to be wild, nothing like what has already been witnessed.

“We know one of the killer apps in the Internet age is advertising,” he said in reference to the opportunities in the mobile advertising that Twitter Inc (NYSE:TWTR) can successfully pursue with a positive cash flow position.

Janeway added that places like China in some aspects are already ahead of the U.S. in terms of mobile advertising. However, said the point is experimentation and what matters for now is that Twitter Inc (NYSE:TWTR) attains positive cash flow.

He concluded by saying that with positive cash flow, Twitter Inc (NYSE:TWTR) will have choices. For example, they can crank up the cost of getting consumers and build more infrastructures.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!